Bibliometric analysis of the usage of tenecteplase for stroke
Dublin Core
Title
Bibliometric analysis of the usage of tenecteplase for stroke
Subject
Tenecteplase, Acute ischemic stroke, Bibliometric analysis
Description
Abstract
Introduction In recent years, tenecteplase has been competing with alteplase as a treatment for acute ischemic
stroke given its ease of administration, lower dosage, cost-effectiveness, and better safety data. This paper seeks to
analyze academic literature regarding the burgeoning usage of tenecteplase as a treatment for acute ischemic stroke
across the world.
Method The Web of Science database was used to collect the data from articles containing the keywords
“Tenecteplase” and “Stroke” published from 1999 to 2023. The search resulted in 576 journal articles. This study
analyzed metadata related to the country, institution, keywords, and date published for each article in the database
pertaining to tenecteplase use for stroke.
Results The United States led in publications (260, 39.93%), followed by Australia (101, 15.51%), and a tie for third
place between Canada and China (77, 11.83% each). The three most prevalent keywords were tenecteplase (N=324),
alteplase (N=284), and thrombolysis (N=244). The University of Melbourne and the University of Calgary were
the leading institutions publishing on the use of tenecteplase as a treatment for stroke. In 2023, the number of
publications on the usage of tenecteplase for stroke was the greatest, making up 24.3% of all papers on the topic.
Conclusion The surge in academic papers regarding tenecteplase in stroke in 2023 could be a good indicator
of the drug’s increasing prevalence as a treatment for stroke. Despite this finding, tenecteplase is currently not an
FDA-approved therapy in the US as Genentech, the drug’s manufacturer, has yet to file for federal approval for acute
ischemic stroke treatment.
Keywords Tenecteplase, Acute ischemic stroke, Bibliometric analysis
Introduction In recent years, tenecteplase has been competing with alteplase as a treatment for acute ischemic
stroke given its ease of administration, lower dosage, cost-effectiveness, and better safety data. This paper seeks to
analyze academic literature regarding the burgeoning usage of tenecteplase as a treatment for acute ischemic stroke
across the world.
Method The Web of Science database was used to collect the data from articles containing the keywords
“Tenecteplase” and “Stroke” published from 1999 to 2023. The search resulted in 576 journal articles. This study
analyzed metadata related to the country, institution, keywords, and date published for each article in the database
pertaining to tenecteplase use for stroke.
Results The United States led in publications (260, 39.93%), followed by Australia (101, 15.51%), and a tie for third
place between Canada and China (77, 11.83% each). The three most prevalent keywords were tenecteplase (N=324),
alteplase (N=284), and thrombolysis (N=244). The University of Melbourne and the University of Calgary were
the leading institutions publishing on the use of tenecteplase as a treatment for stroke. In 2023, the number of
publications on the usage of tenecteplase for stroke was the greatest, making up 24.3% of all papers on the topic.
Conclusion The surge in academic papers regarding tenecteplase in stroke in 2023 could be a good indicator
of the drug’s increasing prevalence as a treatment for stroke. Despite this finding, tenecteplase is currently not an
FDA-approved therapy in the US as Genentech, the drug’s manufacturer, has yet to file for federal approval for acute
ischemic stroke treatment.
Keywords Tenecteplase, Acute ischemic stroke, Bibliometric analysis
Creator
Garv Bhasin1
and Latha Ganti2,3*
and Latha Ganti2,3*
Source
https://doi.org/10.1186/s12245-024-00738-7
Date
2024
Contributor
Peri Irawan
Format
pdf
Language
english
Type
text
Files
Collection
Citation
Garv Bhasin1
and Latha Ganti2,3*, “Bibliometric analysis of the usage of tenecteplase for stroke,” Repository Horizon University Indonesia, accessed April 25, 2026, https://repository.horizon.ac.id/items/show/12496.